Literature DB >> 24677115

Role of interleukin-6 in differentiating interleukin-11 induced fever and early bacterial infection.

Juan Liang1, Zhiyu Lei, Xiaojun Xu, Ning Zhao, Hua Song, Shilong Yang, Fenying Zhao, Junqing Mao, Chan Liao, Diying Shen, Yongmin Tang.   

Abstract

OBJECTIVE: To evaluate the role of Th1/Th2 cytokines (IL-2, IL-4, IL-6, IL-10, TNF-α, IFN-γ) in differentiating interleukin 11 induced fever with C-reactive protein elevation from early bacterial infection.
METHODS: A total of 74 patients were enrolled in this retrospective study. Serum Th1/Th2 cytokines were determined using cytometric bead array (CBA) techniques. Whenever the patients had febrile disease or elevated CRP, systemic inflammatory signs, procalcitonin (PCT), blood culture and X-ray examination were done. The patients were assigned into infected and non-infected groups based on the clinical and laboratory findings.
RESULTS: The CRP levels in both the groups were significantly increased, but no statistically significant difference was found (P = 0.574). IL-6 levels of the infected group were significantly elevated with simultaneously elevated IL-10 levels in a proportion of the patients. IL-6 levels of non-infected patients were normal. IL-6 and IL-10 levels of infected patients were significantly higher than those of non-infected patients (P = 0.005, 0.015, respectively).
CONCLUSIONS: For the patients treated with recombinant human interleukin 11 (rhIL-11), IL-6 and IL-10 measurements can be a useful adjuvant tool for the differentiation of rhIL-11 induced fever with C-reactive protein elevation from early bacterial infection.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24677115     DOI: 10.1007/s12098-014-1361-3

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  18 in total

Review 1.  Severe sepsis and septic shock. Definitions, epidemiology, and clinical manifestations.

Authors:  R A Balk
Journal:  Crit Care Clin       Date:  2000-04       Impact factor: 3.598

Review 2.  Current issues with platelet transfusion in patients with cancer.

Authors:  J McCullough
Journal:  Semin Hematol       Date:  2000-04       Impact factor: 3.851

Review 3.  Platelet transfusion therapy.

Authors:  Sherrill J Slichter
Journal:  Hematol Oncol Clin North Am       Date:  2007-08       Impact factor: 3.722

4.  Low-dose interleukin-11 in patients with bone marrow failure: update of the M. D. Anderson Cancer Center experience.

Authors:  A-M Tsimberidou; F J Giles; I Khouri; C Bueso-Ramos; S Pilat; D A Thomas; J Cortes; R Kurzrock
Journal:  Ann Oncol       Date:  2005-01       Impact factor: 32.976

5.  Serum soluble interleukin-2 receptor, interleukin-6 and tumor necrosis factor alpha as markers of celiac disease activity.

Authors:  Akshay Kapoor; A K Patwari; Praveen Kumar; Anju Jain; Shashi Narayan
Journal:  Indian J Pediatr       Date:  2012-07-06       Impact factor: 1.967

Review 6.  FDA licensure of NEUMEGA to prevent severe chemotherapy-induced thrombocytopenia.

Authors:  J A Kaye
Journal:  Stem Cells       Date:  1998       Impact factor: 6.277

Review 7.  Targeted approaches for the treatment of thrombocytopenia.

Authors:  G D Demetri
Journal:  Oncologist       Date:  2001

8.  Tolerability and side-effect profile of rhIL-11.

Authors:  J W Smith
Journal:  Oncology (Williston Park)       Date:  2000-09       Impact factor: 2.990

9.  Early diagnostic and prognostic significance of a specific Th1/Th2 cytokine pattern in children with haemophagocytic syndrome.

Authors:  Yongmin Tang; Xiaojun Xu; Hua Song; Shilong Yang; Shuwen Shi; Jian Wei; Binhua Pan; Fenying Zhao; Chan Liao; Chunfang Luo
Journal:  Br J Haematol       Date:  2008-07-31       Impact factor: 6.998

Review 10.  [The diagnostic value of procalcitonin in severe sepsis].

Authors:  Judita Andrejaitiene
Journal:  Medicina (Kaunas)       Date:  2006       Impact factor: 2.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.